Ultragenyx: One Biotech IPO To Stalk This Week – Updated
Research - Update from Friday, January 31st at 9:45 AM ET Today the company revealed that it’s selling 5.76M shares at $21. What would have originally been … Continue Reading
Premium: Read NowResearch
Three Updates on Three Names PropThink Suggested for the First Half of This Year
Research - With the JP Morgan Healthcare conference in the rearview, here are updates on a few names that PropThink suggested already this year, all of which … Continue Reading
Premium: Read Now
Linzess Sales Ramp Reads Positive for Synergy Pharma
Research - Ironwood Pharmaceuticals (IRWD) reported financial results for the fourth quarter and full year 2013 on Tuesday morning. We’re interested primarily for the read-through on Synergy Pharmaceuticals … Continue Reading
Read Now
Updated: BioLife Solutions’ Uplisting, Debt Deal Provide Overlooked Opportunity
Research - Update after the bell, BioLife announces a 1:14 reverse split. Talk about timing. BioLife Solutions (BLFS) (which Mr. Deryugin wrote about this morning below and in advance … Continue Reading
Read Now
One Way to Play Sarepta in 2014
Research - Shares of Sarepta Therapeutics (SRPT) have been under pressure this week following a downgrade and ‘Sell’ rating from Citigroup, with a $13 price target. Recall … Continue Reading
Premium: Read Now
Durect Signs a Partner with Another PDUFA Just a Month Out
Research - Durect (DRRX) on Tuesday announced an agreement with Impax Laboratories (IPXL) for the exclusive worldwide rights to develop and commercialize ELADUR, Durect’s investigational transdermal bupivacaine … Continue Reading
Premium: Read Now
Tekmira Continues to ‘Rebrand’
Research - Tekmira Pharmaceuticals (TKMR) continues to recast itself as a pipeline, product-focused company, steering away from investors’ long-time perception of the Canadian firm as a developer … Continue Reading
Premium: Read Now